Literature DB >> 16541267

[Respiratory failure due to delta-9-tetrahydrocannabinol in a tetraplegic patient].

M Neuburger1, M Schley, M Schmelz, G Schuepfer, C Konrad.   

Abstract

We report on a patient with an incomplete tetraplegia below C2 who suffered from a post-traumatic abdominal spasticity, spasticity of the legs, and bladder contractions of high intensity. Breathing was possible during the day using accessory respiratory musculature. All standard therapeutic regimes against spasticity failed. Treatment was started with delta-9-tetrahydrocannabinol administered orally in a dosage of 2 x 2.5 mg/day. The spasticity of the legs and the bladder improved with the treatment. After 3 days, the patient complained about dyspnea and shortness of breath. Treatment with delta-9-tetrahydrocannabinol was discontinued after 5 days but the patient needed ventilatory support for 1 week. After 1 week, spontaneous breathing was possible again. The reasons for respiratory failure in endangered patients during treatment with delta-9-tetrahydrocannabinol could be effects such as sedation, combined treatment with baclofen, muscle weakness, or central nervous effects in the medulla oblongata.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541267     DOI: 10.1007/s00482-006-0474-7

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  20 in total

Review 1.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

2.  Intravenous delta9-Tetrahydrocannabinol: Effects of ventilatory control and cardiovascular dynamics.

Authors:  L A Malit; R E Johnstone; D I Bourke; R A Kulp; V Klein; T C Smith
Journal:  Anesthesiology       Date:  1975-06       Impact factor: 7.892

Review 3.  The safety of cannabinoids for the treatment of multiple sclerosis.

Authors:  Paul F Smith
Journal:  Expert Opin Drug Saf       Date:  2005-05       Impact factor: 4.250

4.  Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human.

Authors:  R S Martin; L A Luong; N J Welsh; R M Eglen; G R Martin; S J MacLennan
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 5.  Endocannabinoid signaling in the brain.

Authors:  Rachel I Wilson; Roger A Nicoll
Journal:  Science       Date:  2002-04-26       Impact factor: 47.728

Review 6.  [Therapeutic use of cannabinoids in neurology].

Authors:  P Schwenkreis; M Tegenthoff
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

7.  Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.

Authors:  Derick T Wade; Petra Makela; Philip Robson; Heather House; Cynthia Bateman
Journal:  Mult Scler       Date:  2004-08       Impact factor: 6.312

8.  Cannabis effect on spasticity in spinal cord injury.

Authors:  J Malec; R F Harvey; J J Cayner
Journal:  Arch Phys Med Rehabil       Date:  1982-03       Impact factor: 3.966

9.  Breathlessness associated with abdominal spastic contraction in a patient with C4 tetraplegia: a case report.

Authors:  Isabelle Laffont; Marie-Christine Durand; Celia Rech; Annie Perez De La Sotta; Nicholas Hart; Olivier Dizien; Frédéric Lofaso
Journal:  Arch Phys Med Rehabil       Date:  2003-06       Impact factor: 3.966

Review 10.  The therapeutic potential of cannabis.

Authors:  David Baker; Gareth Pryce; Gavin Giovannoni; Alan J Thompson
Journal:  Lancet Neurol       Date:  2003-05       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.